Hamilton-based Genesis Drug Discovery & Development, the contract research organization of Genesis Biotechnology Group, announced it has appointed Olesia Buiakova its new chief scientific officer.
Buiakova will be responsible for managing the company’s entire portfolio of drug discovery services. She will also head development and management of new preclinical drug discovery platforms in oncology, immunology, metabolic and ocular diseases.
Buiakova began her career with GBG as vice president of biology for Invivotek in 2013. Later, she transitioned into her current role as chief scientific officer of Invivotek.
Prior to joining GBG, Buiakova held multiple positions in vivo pharmacology including director at Taconic CRO Division.
“We are grateful to Olesia for her previous scientific leadership, and look forward to continuing to work closely with her in her newly expanded role as an advisor and collaborative partner to pharmaceutical, sponsor and academic organizations,” said Dr. Eli Mordechai, CEO of Genesis Biotechnology Group.
